STAT June 20, 2024
Zealand Pharma on Thursday reported early positive results of an investigational obesity drug that activates a hormone that’s not targeted by popular treatments Wegovy and Zepbound.
In one part of a Phase 1b study, petrelintide, which targets the amylin hormone, led to 8.6% weight loss at 16 weeks, more than the 1.7% weight loss among patients taking placebo,...